-
Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH.
Obstet Gynecol 2006;107:6-10. -
Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study.
Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH.
BMJ 2006;332:452-5. -
Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness.
Vandecruys H, Faiola S, Auer M, Sebire N, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:551-3. -
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
Increased nuchal translucency with normal karyotype.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1005-21. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan.
Faiola S, Tsoi E, Huggon IC, Allan LD, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:22-7. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K, Bindra R, Cacho AM, Nicolaides KH.
Prenat Diagn 2004;24:169-73. -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K, Nicolaides KH.
BJOG 2003;110:276-80. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10.